Last reviewed · How we verify

Dexmedetomidine maintenance

University of Pennsylvania · FDA-approved active Small molecule Quality 5/100

Dexmedetomidine maintenance is a Small molecule drug developed by University of Pennsylvania. It is currently FDA-approved. Also known as: Precedex, Dexmedetomidine Hydrochloride.

At a glance

Generic nameDexmedetomidine maintenance
Also known asPrecedex, Dexmedetomidine Hydrochloride
SponsorUniversity of Pennsylvania
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dexmedetomidine maintenance

What is Dexmedetomidine maintenance?

Dexmedetomidine maintenance is a Small molecule drug developed by University of Pennsylvania.

Who makes Dexmedetomidine maintenance?

Dexmedetomidine maintenance is developed and marketed by University of Pennsylvania (see full University of Pennsylvania pipeline at /company/university-of-pennsylvania).

Is Dexmedetomidine maintenance also known as anything else?

Dexmedetomidine maintenance is also known as Precedex, Dexmedetomidine Hydrochloride.

What development phase is Dexmedetomidine maintenance in?

Dexmedetomidine maintenance is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing